Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2010 Dec;9(6):419-24.
doi: 10.1016/j.jcf.2010.08.008.

Comparison of 7-day and repeated 24-hour recall of symptoms of cystic fibrosis

Antonia V Bennett  1 , Donald L Patrick, James F Lymp, Todd C Edwards, Christopher H Goss
Affiliations
Comparative Study

Comparison of 7-day and repeated 24-hour recall of symptoms of cystic fibrosis

Antonia V Bennett et al. J Cyst Fibros. 2010 Dec.

Abstract

Background: Patient reporting of symptoms in a questionnaire with a 7-day recall period is expected to differ from reporting in daily symptom diaries.

Methods: 38 patients with cystic fibrosis (CF) completed 77 week-long symptom diaries. Each diary day comprised 13 symptom items with 5-point response scales. Days 1-6 of the diary had a 24-hour recall period. Day 7 had a 7-day recall period. Concordance of 7-day recall with summary descriptors of daily reports (e.g. mean, maximum) was examined and ability of 7-day recall and mean of daily reports to discriminate between well and ill periods of health compared.

Results: The average difference in scores was less than 0.25 response scale points. 7-day recall was most concordant with the mean of daily reports. Discriminant ability was comparable.

Conclusions: In this study sample, a questionnaire with 7-day recall provided information similar to a daily diary about the week-long experience of CF symptoms.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement

The authors report no financial or personal relationships which could inappropriately influence this study

Figures

Figure 1.
Figure 1.. CF Respiratory Symptoms Diary (CFRSD) items
Note: This figure describes only the 13 CFRSD items included in this analysis
See this image and copyright information in PMC

References

    1. Gibson R, Burns J, Ramsey B. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003;168:918–51. - PubMed
    1. Goss CH, Edwards TC, Ramsey BW, Aitken ML, Patrick DL. Patient-reported respiratory symptoms in cystic fibrosis. J Cyst Fibros 2009. Jul;8(4):245–52. - PubMed
    1. Revicki DA, Osoba D, Fairclough D, Barofsky I, Berzon R, Leidy NK, et al. Recommendations on health-related quality of life research to support labeling and promotional claims in the United States. Qual Life Res 2000;9(8):887–900. - PubMed
    1. Goss CH, Quittner AL. Patient-reported outcomes in cystic fibrosis. Proc Am Thorac Soc 2007. Aug 1;4(4):378–86. - PMC - PubMed
    1. FDA. Patient Reported Outcome (PRO) Measures: Use in Medical Product Development to Support Labeling Claims. Federal Register. 2009;74(235).

Publication types